Brighton, UK, 21 September 2016 – Destiny Pharma Ltd welcomes today’s United Nation’s meeting in New York where all 193 nations of the UN will sign a landmark declaration to pledge to rid the world of Antibiotic Resistant infections. This is only the fourth time the UN has focused on addressing a global healthcare issue in its history, underlining the worldwide concern on the impact that Antibiotic Resistance will have if left unchecked.

Among a number of actions that the UN will commit to is to encourage innovation for new antibiotics and novel antibacterial drugs, and to address the imbalance in the value of antibiotics to public health and society.

“This is a landmark announcement”, commented Dr Bill Love, CEO, Destiny Pharma, “It signals that the world is now serious about taking significant measures to reverse and address the healthcare crisis caused by antibiotic resistant bacteria. We expect that these positive developments will assist companies such as ours to deliver a pipeline of new and much needed novel antibacterial drugs.”

The United Nations, World Health Organization, Food and Agriculture Organization, and the OIE-World Organisation for Animal Health will provide a report containing a wide range of recommendations for action to address Antibiotic Resistance. The report will be delivered at the 73rd UN General Assembly in 2 years’ time.

For further information please contact:

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Tel: +44 20 3440 5813

Email: destinypharma@humebrophy.com

About Destiny Pharma:

Destiny Pharma, a clinical stage biopharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action that seek to address the global healthcare issue, namely, Antibiotic Resistance. XF-73 is the Company’s lead drug which has completed 5 Phase I/IIa clinical studies in Europe/US. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialize candidates from the XF Drug platform based on dicationic porphyrins which are differentiated from traditional antibiotics structurally. XF drug candidates are able to kill static and growing bacterial cultures, as well as bacteria with biofilm and may thus see limited resistance development. Non-growing cultures often become resistant to traditional antibiotics that rely on the bacteria actively growing to kill them. Additional information on Destiny Pharma is available at www.destinypharma.com

About the NIH and NIAID:

The US clinical trial was performed under DMID contract number HHSN27220800026C.

NIH, the U.S. medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research-at NIH, within the U.S. and worldwide-to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses.

News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.

About Destiny Pharma:

Destiny Pharma, a leading, clinical stage biopharmaceutical company, founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action that seek to address the global healthcare issue, namely, Antibiotic Resistance. Exeporfinium chloride is the Company’s lead drug which has completed 3 Phase I/IIa clinical studies in the UK/Europe. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform based on dicationic porphyrins which are differentiated from traditional antibiotics structurally. XF drug candidates are able to kill static and growing bacterial cultures, as well as bacteria with biofilm and may thus see limited resistance development. Non-growing cultures often become resistant to traditional antibiotics that rely on the bacteria actively growing to kill them. Additional information on Destiny Pharma is available at www.destinypharma.com

References:

1. Wertheim HFL et al. The role of nasal carriage in Staphylococcus aureus infection. Lancet Infectious Diseases (2005); 5: 751-62
2. Perl T et al. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage. Annals of Pharmacotherapy (1998); 32(S): S7-16
3. Sciortino CV et al. Surveillance of methicillin-resistant Staphylococcus aureus mupirocin resistance in a Veterans Affairs hospital. Infection Control & Hospital Epidemiology (2015); 36(2): 235-6
4. Destiny Pharma Press Release dated 11 November 2015. Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphyloccocal Infections.
5. Klevens RM et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA (2007); 298(13): 1763-71
6. Suaya JA et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC infectious diseases (2014); 14: 296
7. Teillant A et al. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infectious Diseases (2015); 298(15): 1429-37
8. Farrell D et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy (2011); 55(3): 1177-81

Forward Looking Statement:

This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward-looking statements except as required by law.

Final report of Government’s AMR Review calls for $1 billion reward for new drugs.

Adoption of this and other recommendations is on the G7, G20 & United Nations main agendas in May and September this year.

Destiny Pharma’s XF drugs are a novel antibacterial approach, with a rapid bacterial kill and the capability to address AMR, and are already in advanced clinical development in the UK & US

Brighton, UK, 19 May 2016: – Destiny Pharma Ltd, a leading clinical stage pharmaceutical company focused on developing antibacterial medicines, is pleased to welcome and applaud the final report and recommendations of the UK Review on Antimicrobial Resistance (AMR Review) chaired by Lord O’Neill.

In July 2014, the UK Government commissioned the Review on Antimicrobial Resistance in collaboration with the Wellcome Trust. The Review is independent and engages widely with international stakeholders to understand and propose solutions to the problem of antimicrobial resistance, from an economic and social perspective and outlines 10 areas where the world needs to take action to tackle AMR. Many of these measures focus on reduction of antibiotic resistant infections, incentivising industry to develop much needed new drugs and infection prevention approaches.

Dr Bill Love, CEO of Destiny Pharma commented: “Antibiotic resistance is a recognised global threat. If not addressed, it is predicted to have a greater impact than cancer, a $100 trillion annual global cost and is the harbinger of the end of modern medicine as we know it. We welcome the final report and recommendations of the Review of Antimicrobial Resistance. Addressing the lack of development of new antibiotics, and the urgent need for novel antibacterial drugs – ideally ones which counter bacterial drug resistance – is of paramount importance”.

“There has been an absence of big pharma in the development of antibiotics – smaller, independent companies like Destiny Pharma have driven innovation in recent years and have products close to market. The proposal for Market Entry Rewards as outlined in the O’Neill report potentially rewarding companies with a $1 billion payment upon new drug approval, would be a shot in the arm for developing much needed new drugs. The report also recommends a Play or Pay levy on big pharma to help fund new products, which is offset if they already develop drugs in this area. Adoption and implementation of the report recommendations is estimated to cost $4 billion a year, a fraction (0.05%) of the G20’s spend on healthcare and a small price to pay to address this global crisis. Political consensus will be crucial in delivering these recommendations and we look forward to the discussions at the forthcoming global forums, including the G7, G20 and for the first time AMR is on the high level agenda of United Nations General Assembly meeting.”

One of Destiny Pharma’s XF drug product developments is an antibacterial drug that tackles the prevention of post-surgical bacterial infection, including antibiotic resistant bacteria – a major cause of hospital infection. The lead drug candidate XF-73, has completed 4 clinical studies in the UK and shown to reduce the number of bacteria rapidly, with a US clinical trial to be reported shortly. In laboratory tests XF-73 has been shown not to succumb to bacterial resistance – unlike traditional antibiotics. XF-73 was granted Qualifying Infectious Disease Product (QIDP) status in October 2015 by the FDA for a new US indication for the, ‘Prevention of post-surgical staphylococcal infections’.

Dr Bill Love added: “At Destiny Pharma our innovative drug development has already produced the revolutionary XF drug series. Evidence shows that the likelihood of bacterial resistance developing to these drugs is remote – offering a totally new means to prevent and treat certain bacterial infections. The stimulus of the AMR Report recommendations will assist us to achieve our goal of a new range of novel antimicrobial drug products.”

For further information please contact:
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 20 3440 5813
Email: destinypharma@humebrophy.com

About Destiny Pharma:
Destiny Pharma, a leading, clinical stage biopharmaceutical company, founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action that seek to address the global healthcare issue, namely, Antibiotic Resistance. Exeporfinium chloride is the Company’s lead drug which has completed 4 Phase I/IIa clinical studies in the UK/Europe. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialize candidates from the XF Drug platform based on dicationic porphyrins which are differentiated from traditional antibiotics structurally. XF drug candidates are able to kill static and growing bacterial cultures, as well as bacteria with biofilm and may thus see limited resistance development. Non-growing cultures often become resistant to traditional antibiotics that rely on the bacteria actively growing to kill them. Additional information on Destiny Pharma is available at www.destinypharma.com.

About infections and hospital admissions:
Infection remains a major complication for hospital admissions. The
most common cause of infection is the bacteria Staphylococcus aureus
(SA), including the antibiotic resistant form, MRSA. Infection prevention
measures including decolonisation of SA/MRSA ahead of surgery in at-risk
patients are now practised in many countries, but the continuing problem
of bacterial resistance prevents the procedure being extended to the
larger number of patients who could benefit. There is an urgent global
need for drugs that can effectively prevent SA infections in patients
without succumbing to bacterial resistance. In the USA alone it is estimated
drug-resistant forms of SA such as MRSA result in 19,000 deaths per
year. The annual cost of Staphylococcus aureus infection in the
US is put at $9.5 billion.

A report in The Lancet 15th October 2015, estimates that between
38 – 51% of bacteria that cause post-surgical infections are resistant
to traditional antibiotics used and that a 30% reduction in current
antibiotic effectiveness could result in 120,000 additional post-surgical
and chemotherapy related infections in the USA alone.

Forward Looking Statement:
This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward-looking statements except as required by law.

11th November 2015, Brighton, UK – Destiny
Pharma Ltd, a leading, clinical stage biopharmaceutical companyfocused
on developing and commercialising antibacterial drug products, today
announced that the US Food and Drug Administration (FDA) has granted
Qualified Infectious Disease Product (QIDP) designation to Destiny Pharma’s
lead drug product candidate, XF-73, (Exeporfinium chloride). This is
a novel, synthetic drug with anti-bacterial activity against a broad
range of bacteria. The drug is being developed against the bacteria,
Staphylococcus aureus, including the multi-antibiotic resistant
strain, Methicillin-Resistant Staphylococcus aureus, (MRSA).

The QIDP designation for XF-73 is for the prevention of post-surgical
Staphylococcal infections and there are tens of millions of patients
entering hospitals each year who are at significant risk of contracting
a post-surgical infection because they ‘carry’ this bacteria. Under
the GAIN (Generating Antibiotic Incentives Now) Act, QIDP status confers
FDA priority review, eligibility for fast-track status and an additional
five-year extension of US patent exclusivity when approval is granted.

The FDA grants QIDP designations to drugs intended to treat serious
or life-threatening infections, caused by “qualified pathogens”. These
pathogens include the hospital Superbug, MRSA, one of the leading causes
of post-surgical infections.

Data from four Phase I/IIa studies in Europe has shown that XF-73 is
rapidly bactericidal i.e. reducing the number of bacteria in the nose
quickly. Coupled with the unique property to prevent bacterial resistance
demonstrated in laboratory tests (1), XF-73 promises to be able to prevent
potentially fatal Staphylococcus aureus infections. An approach
which is becoming compromised due to a limited number of antibiotics
and antibiotic resistance. In the USA, a clinical trial of XF-73 is
sponsored and funded by the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health (NIH), and
is expected to complete shortly.

Dr Bill Love, CEO of Destiny Pharma, commented: “The QIDP designation
is an important milestone in the development of our lead product XF-73
which represents a new approach in hospital infection prevention for
millions of surgical patients. Around the world, governments and global
organisations are calling for new anti-bacterial drugs and are introducing
incentives to reward companies for delivering these products. Tackling
Antibiotic Resistance is on the G7 agenda and industry is starting to
return to this space. XF-73 has a novel bacterial-killing action which
offers the potential of a more comprehensive surgical infection prevention
program.”

For further information please contact:
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 20 3440 5813
Email: destinypharma@humebrophy.com

About Destiny Pharma:
Destiny Pharma, a clinical stage biopharmaceutical company, was founded
in 1997. The Company focuses on the R&D of new antimicrobial drugs,
with an emphasis on novel mechanisms of action that seek to address
the global healthcare issue, namely, Antibiotic Resistance. XF-73 is
the Company’s lead drug which has completed 4 Phase I/IIa clinical studies
in the UK/Europe. Through its extensive business network and strategic
partnerships, Destiny Pharma intends to globally commercialise candidates
from the XF Drug platform based on dicationic porphyrins which are differentiated
from traditional antibiotics structurally. XF drug candidates are able
to kill static and growing bacterial cultures, as well as bacteria with
biofilm and may thus see limited resistance development. Non-growing
cultures often become resistant to traditional antibiotics that rely
on the bacteria actively growing to kill them. Additional information
on Destiny Pharma is available at www.destinypharma.com

About infections and hospital admissions:
Infection remains a major complication for hospital admissions. The
most common cause of infection is the bacteria Staphylococcus aureus
(SA), including the antibiotic resistant form, MRSA. Infection prevention
measures including decolonisation of SA/MRSA ahead of surgery in at-risk
patients are now practised in many countries, but the continuing problem
of bacterial resistance prevents the procedure being extended to the
larger number of patients who could benefit. There is an urgent global
need for drugs that can effectively prevent SA infections in patients
without succumbing to bacterial resistance. In the USA alone it is estimated
drug-resistant forms of SA such as MRSA result in 19,000 deaths per
year. The annual cost of Staphylococcus aureus infection in the
US is put at $9.5 billion.

A report in The Lancet 15th October 2015 (2), estimates that between
38 – 51% of bacteria that cause post-surgical infections are resistant
to traditional antibiotics used and that a 30% reduction in current
antibiotic effectiveness could result in 120,000 additional post-surgical
and chemotherapy related infections in the USA alone.

References:
1. David Farrell et al., “Investigation of the potential for
mutational resistance to XF-73, Retapamulin, Mupirocin, Daptomycin,
Fusidic acid & Vancomycin in MRSA isolates during a 55 passage study”.
Antimicrob.Agents & Chemo., (2011), p1177
2. Aude Teillant et al., “Potential burden of antibiotic resistance
on surgery and cancer chemotherapy antibiotic prophylaxis in the USA:
a literature review and modelling study.”, The Lancet Online, 15th Oct
2015. http://dx.doi.org/10.1016/S1473-3099(15)00270-4

Forward Looking Statement:
This press release contains forward-looking statements that are subject
to risks and uncertainties and includes statements that are not historical
facts. Actual results could differ significantly from results discussed.
Destiny Pharma disclaims any intent or obligation to update forward-looking
statements except as required by law.